Keywords: Amgen, colon cancer, Vectibex, Folfox, chemotherapy drugs

Amgen scores with cancer drug, says Zacks analysts

Article | 10 August 2009

Print This

After the close of market on August 6, US biotechnology major Amgen announced that the longevity of colon cancer patients improved ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in